By systematically examining this wide array of disorders, the study sheds light on the potential therapeutic roles of GLP-1RAs beyond their established metabolic applications
Clinical Evidence A study published in the New England Journal of Medicine followed 47 MCAS patients : 89% showed improvement in symptoms, including allergic, neurologic, digestive, and inflammation-related reactions Improvements happened within hours to days Only 13% experienced weight loss , and none became underweight Consistency is crucial
For semaglutide, the abdomen is generally the preferred starting site due to its faster absorption and ease of access
Feel anxious about stopping medication
What patients really need is evidence-based care that allows clinicians to adjust dosing over time so were using the right dose for the right patient at the right time. GLP-1 medications can be a game-changer, but they work best when used as part of a broader strategy that includes nutrition, physical activity and long-term support
